Suppr超能文献

在急性感染性心内膜炎期间,使用主动脉同种异体移植物进行主动脉瓣置换术已有20多年的经验。

Over 20 years experience with aortic homograft in aortic valve replacement during acute infective endocarditis.

作者信息

Solari Silvia, Mastrobuoni Stefano, De Kerchove Laurent, Navarra Emiliano, Astarci Parla, Noirhomme Philippe, Poncelet Alain, Jashari Ramadan, Rubay Jean, El Khoury Gebrine

机构信息

Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.

Division of Cardiothoracic and Vascular Surgery, Cliniques Universitaires Saint-Luc, Brussels, Belgium.

出版信息

Eur J Cardiothorac Surg. 2016 Dec;50(6):1158-1164. doi: 10.1093/ejcts/ezw175. Epub 2016 May 26.

Abstract

OBJECTIVES

Despite the controversy, the aortic homograft is supposedly the best option in acute infective endocarditis (AIE), due to its resistance to reinfection. However, the technical complexity and the risk of structural deterioration over time have limited its utilization. The aim of this study was to evaluate the long-term results of aortic homograft for the treatment of infective endocarditis in our institution with particular attention to predictors of survival and homograft reoperation.

METHODS

The cohort includes 112 patients who underwent aortic valve replacement with an aortic homograft for AIE between January 1990 and December 2014.

RESULTS

Fifteen patients (13.4%) died during the first 30 days after the operation. Two patients were lost to follow-up after discharge from the hospital; therefore, 95 patients were available for long-term analysis. The median duration of follow-up was 7.8 years (IQR 4.7-17.6). Five patients (5.3%) suffered a recurrence of infective endocarditis (1 relapse and 4 new episodes). Sixteen patients (16.8%) were reoperated for structural valve degeneration (SVD; n = 14, 87.5%) or for infection recurrence (n = 2, 12.5%). Freedom from homograft reoperation for infective endocarditis or structural homograft degeneration at 10 and 15 years postoperatively was 86.3 ± 5.5 and 47.3 ± 11.0%, respectively. For patients requiring homograft reoperation, the median interval to reintervention was 11.6 years (IQR 8.3-14.5). Long-term survival was 63.6% (95% CI 52.4-72.8%) and 53.8% (95% CI 40.6-65.3%) at 10 and 15 years, respectively.

CONCLUSIONS

The use of aortic homograft in acute aortic valve endocarditis is associated with a remarkably low risk of relapsing infection and very acceptable long-term survival. The risk of reoperation due to SVD is significant after one decade especially in young patients. The aortic homograft seems to be ideally suited for reconstruction of the aortic valve and cardiac structures damaged by the infective process especially in early surgery.

摘要

目的

尽管存在争议,但由于主动脉同种异体移植物具有抗再感染能力,它被认为是急性感染性心内膜炎(AIE)的最佳选择。然而,技术复杂性和随着时间推移结构恶化的风险限制了其应用。本研究的目的是评估在我们机构中使用主动脉同种异体移植物治疗感染性心内膜炎的长期结果,特别关注生存预测因素和同种异体移植物再次手术情况。

方法

该队列包括1990年1月至2014年12月期间因AIE接受主动脉同种异体移植物主动脉瓣置换术的112例患者。

结果

15例患者(13.4%)在术后30天内死亡。2例患者出院后失访;因此,95例患者可进行长期分析。随访的中位时间为7.8年(四分位间距4.7 - 17.6年)。5例患者(5.3%)发生感染性心内膜炎复发(1例复发和4例新发发作)。16例患者(16.8%)因结构性瓣膜退变(SVD;n = 14,87.5%)或感染复发(n = 2,12.5%)接受再次手术。术后10年和15年因感染性心内膜炎或结构性同种异体移植物退变而无需进行同种异体移植物再次手术的自由度分别为86.3±5.5%和47.3±11.0%。对于需要进行同种异体移植物再次手术的患者,再次干预的中位间隔时间为11.6年(四分位间距8.3 - 14.5年)。10年和15年的长期生存率分别为63.6%(95%可信区间52.4 - 72.8%)和53.8%(95%可信区间40.6 - 65.3%)。

结论

在急性主动脉瓣心内膜炎中使用主动脉同种异体移植物与复发感染风险极低和非常可观的长期生存率相关。十年后因SVD进行再次手术的风险显著,尤其是在年轻患者中。主动脉同种异体移植物似乎非常适合重建因感染过程受损的主动脉瓣和心脏结构,特别是在早期手术中。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验